Clinical features of lung cancer in patients with connective tissue diseases: A 10-year hospital based study

Respiratory Medicine

Volumn 102, Issue 4, 2008, Pages 620-624

  Adžić, Tatjana N ^a   Pešut, Dragica P ^a   Nagorni Obradović, Ljudmila M ^a   Stojšić, Jelena M ^a   Vasiljević, Mladenko D ^b   Bouros, Demosthenes ^c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b University Clinic of Gynaecology and Obstetrics Narodni Front   (Serbia)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Cancer; Collagen vascular disease; Connective tissue disease; Diagnosis; Lung cancer; Survival

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CIGARETTE SMOKING; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HISTOLOGY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UNIVERSITY HOSPITAL;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; LUNG NEOPLASMS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SCLERODERMA, SYSTEMIC; SMOKING; SURVIVAL RATE;

EID: 40149108333     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.10.022     Document Type: Article

References (26)

1. Bouros D., Hatzakis K., Labrakis H., and Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest 121 (2002) 1278-1289
2. Daniels C.E., and Jett J.R. Does interstitial lung disease predispose to lung cancer. Curr Opin Pulm Med 11 5 (2005) 431-437
3. Hilli C., Nguyon A., Roder D., and Robert-Thompson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62 (2003) 72
4. Zatuchni J., Campbell N., and Zorafonetis D. Pulmonary fibrosis and terminal bronchiolar carcinoma in scleroderma. Cancer 6 (1953) 1147-1158
5. Higuchi M., Horiuchi T., Ishibashi N., et al. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 19 (2000) 123-126
6. Rothfield N., Kurtzman S., Vasques A., et al. Association of anti-topoisomerase 1 with cancer. Arthritis Rheum 35 (1992) 724
7. Roumm D., and Medsgar A. Cancer and systemic sclerosis-an epidemiologic study. Arthritis Rheum 28 (1985) 1336-1340
8. Hilli C., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: combined population data from three Nordic countries. Lancet 357 (2001) 96-100
9. Davis A., Cohen R., McNeese D., et al. Localized scleroderma in breast cancer patients treated with supervoltage external term radiation: radiation post scleroderma. J Am Acad Dermatol 35 (1996) 923-927
10. Hasset G., Harnett P., and Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 19 (2001) 197-200
11. De Angelis R., Bugatti L., Cerioni A., et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 22 (2003) 49-52
12. Kerr D., and Spiera H. Scleroderma in association with the use of bleomycin-a report of 3 cases. J Rheumatol 19 (1992) 294-296
13. Karim M., Vaux E., Davies R., et al. Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer. Clin Nephrol 58 (2002) 384-388
14. Sakkas I., Moore F., and Akritidis C. Cancer in families with systemic sclerosis. Am J Med Sci 310 (1995) 223-225
15. Diot E., Lesire V., Guilmat L., et al. Systemic sclerosis and occupational risk factors: a case control study. Occup Environ Med 59 (2002) 545-549
16. Yang Y., Fujita J., Tokuda M., et al. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21 (2001) 106-111
17. Mellemkjaer L., Linet S., Gridley G., et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 32 (1996) 1753-1757
18. Leandro J., and Isenberg A. Rheumatic diseases and malignancy-is there an association?. Scand J Rheumatol 30 (2001) 185-188
19. Bucca C., and Rolla G. Women: lung and autoimmune disease. Eur Respir Mon 25 (2003) 190-203
20. Chatterjee S., Dombi G.W., Severson R.K., and Mayes M.D. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52 (2005) 2415-2424
21. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 (2002) 1581-1586
22. Rice A.J., Wells A.U., Bouros D., et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. Am J Clin Pathol 119 (2003) 709-714
23. Abu-Shakra M., Guillemin F., and Lee P. Cancer in systemic sclerosis. Arthritis Rheum 36 (1993) 460-464
24. Hesselstrand R., Scheja A., and Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57 (1998) 682-686
25. Irie H., Satoh H., Ahama T., et al. Systemic lupus erythematosus associated with primary large cell carcinoma of the lung. Med Oncol 15 (1998) 289-291
26. Antoniou K.M., Mamoulaki M., Malagari K., Kritikos H.D., Bouros D., Siafakas N.M., et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 25 (2007) 23-28